Preoperative profiles of plasma amino acids and derivatives distinguish periampullary cancer and benign disease.

Autor: Stålberg SM; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department of Natural Sciences and Environmental Health, University of South-Eastern Norway, Bø i Telemark, Norway.; Department of Pathology, Skien Hospital, Vestfold og Telemark, Norway., Silwal-Pandit L; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Bastani NE; Division for Molecular Nutrition, Institute for Basic Medical Sciences, University of Oslo, Oslo, Norway., Nebdal DJH; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Lingjærde OC; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department of Computer Science, University of Oslo, Oslo, Norway., Skålhegg BS; Division for Molecular Nutrition, Institute for Basic Medical Sciences, University of Oslo, Oslo, Norway., Kure EH; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. elin.kure@usn.no.; Department of Natural Sciences and Environmental Health, University of South-Eastern Norway, Bø i Telemark, Norway. elin.kure@usn.no.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2024 May 03; Vol. 24 (1), pp. 555. Date of Electronic Publication: 2024 May 03.
DOI: 10.1186/s12885-024-12320-8
Abstrakt: Periampullary cancers, including pancreatic ductal adenocarcinoma, ampullary-, cholangio-, and duodenal carcinoma, are frequently diagnosed in an advanced stage and are associated with poor overall survival. They are difficult to differentiate from each other and challenging to distinguish from benign periampullary disease preoperatively. To improve the preoperative diagnostics of periampullary neoplasms, clinical or biological markers are warranted.In this study, 28 blood plasma amino acids and derivatives from preoperative patients with benign (N = 45) and malignant (N = 72) periampullary disease were analyzed by LC-MS/MS.Principal component analysis and consensus clustering both separated the patients with cancer and the patients with benign disease. Glutamic acid had significantly higher plasma expression and 15 other metabolites significantly lower plasma expression in patients with malignant disease compared with patients having benign disease. Phenylalanine was the only metabolite associated with improved overall survival (HR = 0.50, CI 0.30-0.83, P < 0.01).Taken together, plasma metabolite profiles from patients with malignant and benign periampullary disease were significantly different and have the potential to distinguish malignant from benign disease preoperatively.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje